Returns couldn't have been much worse for these drugmakers this year.
News & Analysis: OvaScience
OvaScience, Keryx Biopharmaceuticals, and NantKwest have had a rough 2015. Can any of these beaten down biotech stocks rebound or should investors continue to keep their distance?
Lower than expected demand for its in-vitro product overseas is forcing the company to cut its guidance for 2015.
OvaScience co-founder Richard Aldrich has purchased more shares in the company.
OvaScience Inc. shares jumped after Wall Street analysts came to its defense.
OvaScience Inc. shares are jumping on hopes that the company can revolutionize in vitro fertilization.
OvaScience, Agios Therapeutics, and Bluebird bio were among the top performing stocks of 2014.
Here's why Ovascience, Bluebird Bio, and Regulus investors saw their share prices surge last quarter.
OvaScience shareholders check the mail only to find an unwelcome untitled letter from the Food and Drug Administration. Are things really as bad as they appear?